DJIA 17,128.55 -44.13 -0.26%
NASDAQ 4,530.38 2.69 0.06%
S&P 500 1,989.53 -4.76 -0.24%
market minute promo

PTC Therapeutics, Inc. (NASDAQ: PTCT)

40.82 -0.28 (-0.68%)

Quote as of

company name or ticker

Recent Quotes

PTCT $40.82 -0.68%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $41.77
Previous Close $41.10
Daily Range $40.63 - $41.90
52-Week Range $13.15 - $41.90
Market Cap $1.2B
P/E Ratio 1.54
Dividend (Yield) $0.00 (0.0%)
Volume 144,588
Average Daily Volume 312,446
Current FY EPS -$3.46



PTC Therapeutics, Inc. (PTCT) Description

PTC Therapeutics, Inc. Website:

News & Commentary

George Soros Is Betting on This Risky Stock: Should You?

Sarepta Therapeutics is a clinical-stage biotechnology company seeking to gain approval for a potentially game-changing Duchenne muscular dystrophy drug called eteplirsen. Wall Street appears convinced that the drug is a winner, but scientists have been less optimistic. Here's why.

PTC Therapeutics (PTCT) is in Overbought Territory: What's Next? - Tale of the Tape

NASDAQ Biotech Top Performers (Pre-Open September 19)

New Lifetime High Reached: PTC Therapeutics (PTCT)

Insider Trading Alert - CPT, PTCT And LNKD Traded By Insiders

PTC Therapeutics (PTCT) Soars: Stock Rises 11.5% - Tale of the Tape

PTC Therapeutics (PTCT) Soars: Stock Rises 11.5% - Tale of the Tape

Midday Gainers From September 15 - RadioShack Corporation, Rewalk Robotics Ltd And More

Stocks Hitting 52-Week Highs

PTC Therapeutics' (PTCT) CEO Stuart Peltz on Q2 2014 Results - Earnings Call Transcript

PTC Therapeutics: A Speculative Buy On Rare Disease Portfolio And Potential Takeover Target

See More PTCT News...